Sana reports Q4 net loss $80.4M; cash $434M; SC291 IND cleared, expects clinical data this year

Sana Biotechnology, Inc.

Net loss Q4 2022 $80.4M ($0.42/sh) vs $110.7M ($0.60/sh) in Q4 2021; FY2022 net loss $269.5M ($1.43/sh).
Cash and marketable securities $434.0M at Dec 31, 2022, down from $746.9M; cash runway into 2025.
SC291 (CD19-targeted allogeneic CAR T) IND cleared; initial clinical data expected in 2023.
Plans to move manufacturing to Bothell, WA; expects ~$100M cost savings versus Fremont build-out.
Non-GAAP operating cash burn FY2022 $288.3M vs $209.6M; restructuring costs in Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sana Biotechnology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 16, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-003795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.